XML 22 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Current Assets    
Cash and cash equivalents $ 7,843 $ 14,625
Prepaid expenses and other current assets 1,389 1,591
Total Current Assets 9,232 16,216
Property and equipment, net 51 37
Deposits and other assets 6 4
Total Assets 9,289 16,257
Current Liabilities:    
Accounts payable 1,079 142
Accrued liabilities 153 885
Total Current Liabilities 1,232 1,027
Stockholders' Equity    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.001 par value; 100,000,000 shares authorized, 58,535,010 issued and 58,453,528 outstanding and 58,295,808 issued and 58,214,326 outstanding respectively 58 58
Additional paid-in capital 97,651 96,430
Accumulated deficit (89,652) (81,258)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 8,057 15,230
Non-controlling interest 0 0
Total Stockholders’ Equity 8,057 15,230
Total Liabilities and Stockholders’ Equity $ 9,289 $ 16,257